A Review of Randomized Controlled Trials Utilizing Telemedicine for Improving Heart Failure Readmission: Can a Realist Approach Bridge the Translational Divide?
Heart failure
readmission
review
technology
telemedicine
Journal
Clinical Medicine Insights. Cardiology
ISSN: 1179-5468
Titre abrégé: Clin Med Insights Cardiol
Pays: United States
ID NLM: 101525768
Informations de publication
Date de publication:
2019
2019
Historique:
received:
22
01
2019
accepted:
04
06
2019
entrez:
19
7
2019
pubmed:
19
7
2019
medline:
19
7
2019
Statut:
epublish
Résumé
Telemedicine and digital health technologies hold great promise for improving clinical care of heart failure. However, inconsistent and contradictory findings from randomized controlled trials have so far discouraged widespread adoption of digital health in routine clinical practice. We undertook this review study to summarize the study outcomes of the use of exploring the evidence for telemedicine in the clinical care of patients with heart failure and readmissions. We inspected the references of guidelines and searched PubMed for randomized controlled trials published over the past 10 years on the use of telemedicine for reducing readmission in heart failure. We utilized a modified realist review approach to identify the underlying contextual mechanisms for the intervention(s) in each randomized controlled trial, evaluating outcomes of the intervention and understanding how and under what conditions they worked. To provide uniformity, all extracted data were synthesized using adapted domains from the taxonomy for disease management created by the Disease Management Taxonomy Writing Group. A total of 12 papers were eligible, 6 of them supporting and 6 others undermining the use of telemedicine for improving heart failure readmission. In general terms, those studies not supporting the use of telemedicine were multicentre, publicly funded, with large amount of participants, and long duration. The patients had also better rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker and beta-blockers, and telemonitoring and automatic transmission of vital signs were less utilized, in comparison with the studies in which telemedicine use was supported. The analysis of the environment, intensity, content of interventions, method of communication, quality of the underlying model of care and the ability, capability, and interest from health workers can help us to envisage probabilities of success of telemedicine use. A realist lens may aid to understand whom and in which circumstances the use of telemedicine can add any substantial value to traditional models of care. Wider outcome criteria beyond major adverse cardiovascular events, for example, cost efficacy, should also be considered as appropriate for effecting guidelines on care delivery when robust prognostic therapeutics already exist.
Sections du résumé
BACKGROUND
BACKGROUND
Telemedicine and digital health technologies hold great promise for improving clinical care of heart failure. However, inconsistent and contradictory findings from randomized controlled trials have so far discouraged widespread adoption of digital health in routine clinical practice. We undertook this review study to summarize the study outcomes of the use of exploring the evidence for telemedicine in the clinical care of patients with heart failure and readmissions.
METHODS
METHODS
We inspected the references of guidelines and searched PubMed for randomized controlled trials published over the past 10 years on the use of telemedicine for reducing readmission in heart failure. We utilized a modified realist review approach to identify the underlying contextual mechanisms for the intervention(s) in each randomized controlled trial, evaluating outcomes of the intervention and understanding how and under what conditions they worked. To provide uniformity, all extracted data were synthesized using adapted domains from the taxonomy for disease management created by the Disease Management Taxonomy Writing Group.
RESULTS
RESULTS
A total of 12 papers were eligible, 6 of them supporting and 6 others undermining the use of telemedicine for improving heart failure readmission. In general terms, those studies not supporting the use of telemedicine were multicentre, publicly funded, with large amount of participants, and long duration. The patients had also better rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker and beta-blockers, and telemonitoring and automatic transmission of vital signs were less utilized, in comparison with the studies in which telemedicine use was supported. The analysis of the environment, intensity, content of interventions, method of communication, quality of the underlying model of care and the ability, capability, and interest from health workers can help us to envisage probabilities of success of telemedicine use.
CONCLUSIONS
CONCLUSIONS
A realist lens may aid to understand whom and in which circumstances the use of telemedicine can add any substantial value to traditional models of care. Wider outcome criteria beyond major adverse cardiovascular events, for example, cost efficacy, should also be considered as appropriate for effecting guidelines on care delivery when robust prognostic therapeutics already exist.
Identifiants
pubmed: 31316270
doi: 10.1177/1179546819861396
pii: 10.1177_1179546819861396
pmc: PMC6620724
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1179546819861396Déclaration de conflit d'intérêts
Declaration of Conflicting Interests:The authors confirm the agreement with the ICMJE authorship and conflict of interest criteria. The authors have also confirmed that this article is unique and not under consideration or published in any other publication and that they have permission from rights holders to reproduce any copyrighted material.
Références
Eur J Heart Fail. 2001 Jun;3(3):315-22
pubmed: 11378002
J Health Serv Res Policy. 2005 Jul;10 Suppl 1:21-34
pubmed: 16053581
Circulation. 2006 Sep 26;114(13):1432-45
pubmed: 16952985
Med J Aust. 2006 Nov 20;185(10):549-57
pubmed: 17115967
BMJ. 2007 May 5;334(7600):942
pubmed: 17426062
Arch Intern Med. 2008 Feb 11;168(3):316-24
pubmed: 18268174
J Am Coll Cardiol. 2009 Oct 27;54(18):1703-5
pubmed: 19850210
Dtsch Arztebl Int. 2010 Feb;107(8):131-8
pubmed: 20300221
J Am Coll Cardiol. 2010 Jul 27;56(5):372-8
pubmed: 20650358
Cochrane Database Syst Rev. 2010 Aug 04;(8):CD007228
pubmed: 20687083
N Engl J Med. 2010 Dec 9;363(24):2301-9
pubmed: 21080835
N Engl J Med. 2010 Dec 9;363(24):2364-7
pubmed: 21080836
Circulation. 2011 May 3;123(17):1873-80
pubmed: 21444883
BMC Med Res Methodol. 2011 Aug 16;11:115
pubmed: 21843376
Circ Heart Fail. 2012 Jan;5(1):25-35
pubmed: 21956192
Med Educ. 2012 Jan;46(1):89-96
pubmed: 22150200
Circulation. 2012 Jan 3;125(1):e2-e220
pubmed: 22179539
Circulation. 2012 Feb 14;125(6):828-36
pubmed: 22331920
Eur J Heart Fail. 2012 Apr;14(4):438-44
pubmed: 22371525
Eur J Prev Cardiol. 2013 Jun;20(3):431-41
pubmed: 22396248
Implement Sci. 2012 Apr 19;7:33
pubmed: 22515663
Eur J Heart Fail. 2012 Jul;14(7):791-801
pubmed: 22588319
Soc Sci Med. 2012 Dec;75(12):2299-306
pubmed: 22989491
J Med Internet Res. 2012 Sep 28;14(5):e132
pubmed: 23022989
Cardiovasc Ther. 2013 Aug;31(4):230-7
pubmed: 23061492
Circulation. 2013 Aug 20;128(8):873-934
pubmed: 23877260
Int J Equity Health. 2013 Aug 28;12:72
pubmed: 23985017
J Telemed Telecare. 2014 Dec;20(8):468-75
pubmed: 25339632
J Am Geriatr Soc. 2015 Jun;63(6):1175-80
pubmed: 26031737
J Telemed Telecare. 2016 Jul;22(5):282-95
pubmed: 26350543
Cochrane Database Syst Rev. 2015 Oct 31;(10):CD007228
pubmed: 26517969
Circulation. 2016 Jan 26;133(4):e38-360
pubmed: 26673558
JAMA Intern Med. 2016 Mar;176(3):310-8
pubmed: 26857383
Healthc (Amst). 2016 Mar;4(1):11-4
pubmed: 27001093
J Med Internet Res. 2016 Apr 17;18(5):e91
pubmed: 27154462
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Curr Heart Fail Rep. 2017 Feb;14(1):40-47
pubmed: 28215030
BMC Cardiovasc Disord. 2017 Jun 14;17(1):156
pubmed: 28615004
Lancet. 2018 Sep 22;392(10152):1047-1057
pubmed: 30153985